Horizon Therapeutics Public Ltd Co
Report results of the KRYSTEXXA PROTECT trial in kidney transplant patients
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 24 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- November 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Results are expected in the fourth quarter of 2021.”
What we found
Evidence strength A What the grades mean
Final PROTECT trial results were presented at ASN Kidney Week in November 2021, before the fourth-quarter 2021 deadline, per a 2022 8-K.
-
A Horizon Therapeutics Public Ltd Co 8-K filed 2022-03-01
“were presented at the American Society of Nephrology (ASN) Kidney Week in November. The data demonstrated that 89% (16 of 18 patients) achieved the primary endpoint at Month 6.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- KRYSTEXXA PROTECT trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Horizon Therapeutics Public Ltd Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C492426-024319 · Corrections policy